Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
RLAY Relay Therapeutics	$3.30 -0.6%	$3.13	$1.78 ▼ $10.72	$565.79M	1.59	2.08 million shs	2.08 million shs
SAGE Sage Therapeutics	$9.15 -1.4%	$7.38	$4.62 ▼ $13.47	$572.97M	0.18	1.28 million shs	4.68 million shs
SLS SELLAS Life Sciences Group	$1.95 -3.9%	$1.63	$0.77 ▼ $2.12	$194.57M	2.26	1.68 million shs	15.87 million shs
STOK Stoke Therapeutics	$11.63 -1.8%	$10.22	$5.35 ▼ $16.15	$635.00M	1.09	673,529 shs	1.37 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
RLAY Relay Therapeutics	0.00%	+3.45%	+9.63%	+25.95%	-49.39%
SAGE Sage Therapeutics	0.00%	-1.61%	+40.77%	+15.09%	-15.75%
SLS SELLAS Life Sciences Group	0.00%	+26.62%	+15.38%	+80.56%	+63.87%
STOK Stoke Therapeutics	0.00%	+0.43%	+21.02%	+74.89%	-13.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
RLAY Relay Therapeutics	2.9054 of 5 stars	3.4	2.0	0.0	3.4	2.5	0.6
SAGE Sage Therapeutics	3.1573 of 5 stars	2.0	2.0	4.0	2.4	1.7	0.6
SLS SELLAS Life Sciences Group	0.3741 of 5 stars	0.0	1.0	0.0	2.1	1.7	0.6
STOK Stoke Therapeutics	3.9845 of 5 stars	3.6	0.0	4.8	2.4	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	435.35% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.93	-2.37% Downside
SLS SELLAS Life Sciences Group	0.00	N/A	N/A	N/A
STOK Stoke Therapeutics	3.29	Buy	$23.20	99.48% Upside

Current Analyst Ratings Breakdown

Latest SLS, RLAY, STOK, and SAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00
5/7/2025	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00
4/25/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/17/2025	RLAY Relay Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$4.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
RLAY Relay Therapeutics	$10.01M	56.52	N/A	N/A	$4.65 per share	0.71
SAGE Sage Therapeutics	$41.24M	13.89	N/A	N/A	$7.60 per share	1.20
SLS SELLAS Life Sciences Group	$1M	194.57	N/A	N/A	$0.13 per share	15.00
STOK Stoke Therapeutics	$36.56M	17.37	N/A	N/A	$4.32 per share	2.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
RLAY Relay Therapeutics	-$337.71M	-$2.23	N/A	N/A	N/A	N/A	-44.17%	-39.53%	8/5/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)
SLS SELLAS Life Sciences Group	-$30.88M	-$0.38	N/A	N/A	N/A	N/A	-193.67%	-113.02%	8/12/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.79	14.72	N/A	N/A	26.33%	19.08%	15.72%	8/5/2025 (Estimated)

Latest SLS, RLAY, STOK, and SAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
RLAY Relay Therapeutics	N/A	19.96	19.96
SAGE Sage Therapeutics	N/A	9.13	9.13
SLS SELLAS Life Sciences Group	N/A	4.64	4.64
STOK Stoke Therapeutics	N/A	8.41	8.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
RLAY Relay Therapeutics	96.98%
SAGE Sage Therapeutics	99.22%
SLS SELLAS Life Sciences Group	17.38%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
RLAY Relay Therapeutics	4.32%
SAGE Sage Therapeutics	5.50%
SLS SELLAS Life Sciences Group	1.20%
STOK Stoke Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
RLAY Relay Therapeutics	330	171.45 million	164.04 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
SLS SELLAS Life Sciences Group	10	99.78 million	98.58 million	Not Optionable
STOK Stoke Therapeutics	100	54.60 million	49.41 million	Optionable

SLS, RLAY, STOK, and SAGE Headlines

Recent News About These Companies

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Buy" from Analysts

2 hours ago | marketbeat.com

STOK Stoke Therapeutics, Inc. - Seeking Alpha

June 29 at 9:44 AM | seekingalpha.com

Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Legend Biotech (LEGN)

June 28 at 3:13 PM | theglobeandmail.com

Stoke-on-Trent bungalow could be turned into children's home

June 28 at 10:12 AM | msn.com

Stoke City confirm new coach appointment as pre-season starts

June 27 at 7:09 PM | msn.com

Traditional Stoke-on-Trent pub reopens for the first time since Covid

June 27 at 7:09 PM | stokesentinel.co.ukS

Stoke Therapeutics (NASDAQ:STOK) Trading Down 3.5% - Here's Why

June 26, 2025 | marketbeat.com

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 17, 2025 | businesswire.com

STOK FY2025 EPS Forecast Lowered by Cantor Fitzgerald

June 16, 2025 | marketbeat.com

Stoke Therapeutics: Impressive Pipeline And Big Backers

June 15, 2025 | seekingalpha.com

Assenagon Asset Management S.A. Sells 391,322 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

June 15, 2025 | marketbeat.com

Cantor Fitzgerald Predicts STOK FY2026 Earnings

June 10, 2025 | marketbeat.com

Kangaroo Care Awareness Day celebrated at Stoke Mandeville Hospital

June 10, 2025 | msn.com

Jong Oranje and Stoke City star is open to transfer: “Of course, I have my ambitions”

June 10, 2025 | sports.yahoo.com

Stoke City confirm next stage of major badge consultation

June 10, 2025 | msn.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

June 10, 2025 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Two Sigma Investments LP

June 9, 2025 | marketbeat.com

Jane Street Group LLC Sells 318,465 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

June 8, 2025 | marketbeat.com

Stoke City Secure Youth International Amid Leeds United Interest

June 7, 2025 | therealefl.co.ukT

Business forum will look at how the Stoke-on-Trent and Staffordshire area sells itself to the world

June 7, 2025 | expressandstar.comE

Five hours of 'thundery showers' to rock Stoke-on-Trent today

June 7, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS, RLAY, STOK, and SAGE Company Descriptions

Relay Therapeutics NASDAQ:RLAY

$3.30 -0.02 (-0.60%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.94 -0.36 (-10.91%)

As of 04:00 AM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sage Therapeutics NASDAQ:SAGE

$9.15 -0.13 (-1.40%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.00 -0.15 (-1.64%)

As of 04:00 AM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SELLAS Life Sciences Group NASDAQ:SLS

$1.95 -0.08 (-3.94%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.94 -0.01 (-0.51%)

As of 04:12 AM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Stoke Therapeutics NASDAQ:STOK

$11.63 -0.21 (-1.77%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.17 -0.46 (-3.96%)

As of 04:02 AM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time